Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Avidity Biosciences
Biotech
Novartis’ centerpiece of $12B Avidity deal flunks ‘crucial’ test
The flop leaves Novartis with one win and two failures from a rapid-fire run of key clinical readouts.
Nick Paul Taylor
Sep 8, 2026 3:34am
Novartis ‘always looking’ for new ways to shuttle drugs to brain
May 28, 2026 8:44am
Atrium arises from Avidity buyout with $270M, preclinical assets
Feb 27, 2026 11:05am
Why Novartis CEO was willing to pay top dollar for Avidity
Nov 20, 2025 4:37am
Novartis pays $12B for late-stage dystrophy biotech Avidity
Oct 26, 2025 4:01pm
Avidity's latest DMD data drop assuages safety concerns: analyst
Mar 17, 2025 2:00pm
